A physician directly
answers your questions.
Consultations are
available at the nearest clinic of
Cosmetic Surgery Seishin.
- March 17, 2009
- The Regenerative Medicine Center will be established in Sapporo in March 2009.
- February 17, 2009
- General director delivered a lecture in America.
- October 1, 2008
- A patent for the Celution™ System was granted.
- September 3, 2008
- The Seishin Regenerative Medicine Center was established at the Fukuoka Clinic in October 2008.
- August 25, 2008
- Breast augmentation by transplantation of adipose tissue-derived stem cells was featured in The Wall Street Journal.
- Home
- >
- New Information
Following the Tokyo, Osaka, and Fukuoka Clinics of Cosmetic Surgery Seishin, the Seishin Regenerative Medicine Center will be established in Sapporo in mid-March 2009. The new center provides Celution™ breast augmentation, or transplantation of adipose stem cells with the Celution™ System.
This November, General Director Kamakura was invited to lecture at the University of California, San Diego, (UCSD) in the United States. In addition, he exchanged information on medical technology with Steven R. Cohen, MD, an authority on plastic surgery in America. He then visited the US head office of Cytori Therapeutics, Inc., a developer of the Celution™ System, to inspect the manufacturing process and to have a meeting for improvement of quality and technology.
Recently granted was a US patent for the Celution™System, which our clinics use for harvesting stem cells in breast augmentation and anti-aging treatment by transplantation of adipose tissue-derived stem cells.
The Celution™ System has already been introduced into three clinics in Japan.
Following the Tokyo and Osaka Clinics, the Fukuoka Clinic also started regenerative medicine by transplantation of adipose tissue-derived stem cells.
Breast augmentation by transplantation of adipose tissue-derived stem cells was featured in The Wall Street Journal on August 19, 2008. This article described breast reconstruction and breast augmentation by transplantation of stem cells, the Celution™ System, and testimonials of patients undergoing Celution™ Breast Augmentation in our clinics.
■The Wall Street Journal
A daily journal specializing in economics published by Dow Jones & Company in New York, United States.
Circulation: About 2 million copies
The detailed information of Celution™ Breast Augmentation is this
The establishment of Seishin Regenerative Medicine Center Tokyo last November was followed by the establishment of the Regenerative Medicine Center at the Cosmetic Surgery Seishin Osaka Clinic (Umeda, Osaka) in May 2008. Now, the Tokyo Clinic and the Osaka Clinic provide regenerative medicine-based treatment, including Celution™ Breast Augmentation by transplantation of adipose tissue-derived stem cells with the Celution™ System.
US Cytori Therapeutics, Inc. (San Diego, CEO Christopher J. Calhoun), the company developing the Celution™ System, a high-precision device for extraction of stem cells, won two categories of the Frost & Sullivan Awards/Innovation of the Year 2008, which are known to be the highest honors awarded by the American health care industry.
Along with the establishment of the Seishin Regenerative Medicine Center, press conference was held at the Hotel Mandarin Oriental Tokyo (Chuo-ku, Tokyo).
- Details of press conference:
- Establishment of Seishin Regenerative Medicine Center at the Cosmetic Surgery Seishin Tokyo Clinic and transplantation of adipose tissue-derived stem cells
- Date:
- November 6 (Tue), 2007
・18:00: Press conference
・19:00: Press reception - Place:
- Linden Room, Hotel Mandarin Oriental Tokyo
■Participating panelists
- Tatsuro Kamakura（General Director of Cosmetic Surgery Seishin, Director of Seishin Regenerative Medicine Center）
- Marc Hedrick（President of Cytori Therapeutics, Inc.）
- Christopher Calhoun（CEO of Cytori Therapeutics, Inc.）
- Keizo Sugimachi（Professor Emeritus at Kyushu University, Director of Kyushu Central Hospital）
- Masumi Miyazaki（Actress）
- Eiko Uchida（President of NPO Bougainvillea）
- Yuji Tominaga（Chief Medical Officer of Beluga Clinic）
- The world’s first breast augmentation with the use of the Celution™ System
- Fully automated accurate procedure for extraction of stem cells to solve problems associated with conventional breast augmentation
- Application of regenerative medicine technology for the establishment of anti-aging medicine on the basis of the patient’s own tissue and potential for self-renewal
Tatsuro Kamakura, the general director of Cosmetic Surgery Seishin, established the Seishin Regenerative Medicine Center at the Cosmetic Surgery Seishin Tokyo Clinic and performed the world’s first breast augmentation by transplantation of adipose tissue-derived stem cells with the use of the CelutionTM System (a medical device for accurate extraction of stem cells from adipose tissue) in the field of cosmetic medicine at the center on Tuesday, November 6, 2007.
In cooperation with the American biotechnology venture Cytori Therapeutics, Inc., Seishin Regenerative Medicine Center will enroll 20 women in a joint clinical study of tissue augmentation with adipose tissue-derived stem cells harvested with the Celution™ System (Cytori Therapeutics, Inc.).
Breast augmentation by transplantation of adipose tissue-derived stem cells is a technology that solves the problems associated with conventional breast augmentation. Common procedures for fat injection have a graft survival of about 30% to 50% after absorption of the majority of injected fat into the body and may be associated with calcification, lump formation, and fat necrosis. In contrast, transplantation of adipose tissue-derived stem cells is expected to allow prolonged retention of transplanted fat with a graft survival of about 70% to 80%. In addition, the use of the Celution™ System allows extraction of stem cells with more consistent purification of the stem cell concentrate resulting in greater purity and higher quality in a shorter time than manual extraction of stem cells.
After the introduction of the technology, Seishin Regenerative Medicine Center at Cosmetic Surgery Seishin expanded the system for application and widespread use of the technology in breast reconstruction and cosmetic medicine (breast augmentation) in cooperation with a group led by Dr. Keizo Sugimachi, professor emeritus at Kyushu University and a pioneer in Celution™ System-based transplantation of adipose tissue-derived stem cells for breast reconstruction in patients with breast cancer. Our efforts come from an increase in the number of patients with breast cancer and resulting increase in breast conserving surgeries in Japan. For women, breast deformation is highly stressful and associated with emotional distress. To help patients relieve the emotional distress of a mastectomy for breast cancer and experience the joy of living is consistent with the treatment policy of Cosmetic Surgery Seishin, that is, to provide cosmetic medicine for improvement in the QOL. Through clinical application of regenerative medicine technologies, primarily technology for transplantation of adipose tissue-derived stem cells, we work to establish anti-aging medicine on the basis of autologous tissue and self-healing potential.
